Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Clazakizumab · LY5724886, ALD-518

Monoclonal antibody · Antagonist of interleukin-6 (IL6) · developed by ELI LILLY &

Phase 2 Most advanced trial
LLY Developer
1 Registered trials

What is Clazakizumab?

Clazakizumab is a humanized monoclonal antibody that binds to and blocks interleukin-6 (IL-6), a pro-inflammatory cytokine. It is being studied in atherosclerosis, cardiovascular disease, obesity, hypertension, type 2 diabetes, and chronic renal insufficiency.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LY5724886, ALD-518, BMS-945429
Drug type
Monoclonal antibody
Targets
interleukin-6 (IL6)
Mechanism
Antagonist of interleukin-6 (IL6)
Therapy area
Cardiovascular, Endocrine, Metabolic, Renal & urology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
4S38Z8RA9O

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07783802 Phase 2 Atherosclerosis Recruiting LLY

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AtherosclerosisCardiovascular DiseaseDiabetes Mellitus, Type 2HypertensionObesityRenal Insufficiency, Chronic

More from ELI LILLY &

Abemaciclib FDA approved Baricitinib FDA approved Donanemab FDA approved Dulaglutide FDA approved Imlunestrant FDA approved Lebrikizumab FDA approved Mirikizumab FDA approved Orforglipron FDA approved Pirtobrutinib FDA approved Selpercatinib FDA approved Tirzepatide FDA approved Brenipatide Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Clazakizumab

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.